- Home
- ZEPP vs RZLT Comparison
ZEPP vs RZLT Comparison
Compare ZEPP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- RZLT
- Stock Information
- Founded
- ZEPP 2013
- RZLT 2010
- Country
- ZEPP Netherlands
- RZLT United States
- Employees
- ZEPP N/A
- RZLT N/A
- Industry
- ZEPP Computer Manufacturing
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- RZLT Health Care
- Exchange
- ZEPP Nasdaq
- RZLT Nasdaq
- Market Cap
- ZEPP 696.3M
- RZLT 626.4M
- IPO Year
- ZEPP N/A
- RZLT N/A
- Fundamental
- Price
- ZEPP $46.87
- RZLT $7.71
- Analyst Decision
- ZEPP
- RZLT Strong Buy
- Analyst Count
- ZEPP 0
- RZLT 4
- Target Price
- ZEPP N/A
- RZLT $11.67
- AVG Volume (30 Days)
- ZEPP 462.5K
- RZLT 921.0K
- Earning Date
- ZEPP 11-17-2025
- RZLT 11-06-2025
- Dividend Yield
- ZEPP N/A
- RZLT N/A
- EPS Growth
- ZEPP N/A
- RZLT N/A
- EPS
- ZEPP N/A
- RZLT N/A
- Revenue
- ZEPP $199,947,000.00
- RZLT N/A
- Revenue This Year
- ZEPP $851.79
- RZLT N/A
- Revenue Next Year
- ZEPP $14.33
- RZLT N/A
- P/E Ratio
- ZEPP N/A
- RZLT N/A
- Revenue Growth
- ZEPP N/A
- RZLT N/A
- 52 Week Low
- ZEPP $2.13
- RZLT $2.22
- 52 Week High
- ZEPP $55.99
- RZLT $8.34
- Technical
- Relative Strength Index (RSI)
- ZEPP 60.22
- RZLT 64.10
- Support Level
- ZEPP $43.31
- RZLT $7.23
- Resistance Level
- ZEPP $54.90
- RZLT $8.34
- Average True Range (ATR)
- ZEPP 5.42
- RZLT 0.36
- MACD
- ZEPP -1.19
- RZLT -0.05
- Stochastic Oscillator
- ZEPP 53.56
- RZLT 55.83
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.